A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer

• Published in: Turkish journal of urology Vol. 43; no. 3; pp. 279 - 283
• Main Authors: Uluocak, Nihat, Atılgan, Doğan, Parlaktaş, Bekir Süha, Erdemir, Fikret, Ateş, Ömer
• Format: Journal Article
• Language: English
• Published: Turkey Aves Yayincilik Ltd. STI 01.09.2017; Turkish Association of Urology
• Subjects: Polymorphism; Prostate cancer; Urology; Urooncology; polymorphism; prostate; paraoxanase 1; Cancer
• ISSN: 2149-3235; 2149-3057; 2980-1478
• DOI: 10.5152/tud.2017.74151

We aimed to show the relationship between paraoxonase 1 (PON1) gene polymorphism and the development of prostate cancer (PCa). We investigated the association of single nuclotide polymorphisms of PON1 enzyme with the development of PCa risk. A total of 147 male patients were divided into PCa, and control groups. The control group was also divided into two subgroups according to serum prostate specific antigen (PSA) levels as non PCa-high PSA (>4 ng/mL) and non PCa-low PSA (≤4 ng/mL) groups. The mean ages of the patients were 64.81 years, 63.27 years and 64.22 years in PCa group, non PCa-low PSA and non PCa -high PSA groups, respectively. The mean PSA levels were 10.9 ng/mL, 1.16 ng/mL and 6.63 ng/mL for PCa group, non PCa -low PSA and non PCa -high PSA groups, respectively. In terms of PON1 polymorphisms and allele frequencies, there were no statistically significant differences between PCa and control groups. There was not a statistically significant difference between PCa and non PCa-high PSA groups as for genotypic and allelic frequencies. As a result of this small sample sized hypothetical study of polymorphism, a relationship could not be detected between PCa development and PON1 gene polymorphism. According to the results of this preliminary study, it is thought that more comprehensive future studies are necessary to clarify the possible role of PON1 gene polymorphism in the etiology of PCa.